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Abstract 
 Viral infectious diseases cause millions of deaths and severe illness all around the 
world affecting public health and economics. Viral vaccines are helping to fight against 
viral diseases, but current vaccines are expensive and unavailable, especially in poor and 
developing countries. When measuring the entire manufacturing processing, the 
downstream processing of vaccines is the major cost of production. Our goal for this 
research is to develop a low-cost alternative downstream processing platform for new 
vaccine manufacturing infrastructures. 
 We have developed a novel osmolyte flocculation method for viral particles. To 
create a platform purification for several types of viral particles, we used two model 
viruses: porcine parvovirus (PPV) and Sindbis virus (SINV). PPV is a non-enveloped 
virus, one of smallest known mammalian viruses with a diameter of approximately 20 
nm. The enveloped virus, SINV, has a size of 48-52 nm.  Using mannitol osmolyte 
flocculation we demonstrated recovery for both viruses by diafiltration using a micropore 
membrane. This will allow easy scale-up to production scale and creates a low cost 
platform. Our lab’s previous study showed that osmolyte flocculation was specific to 
viruses as compared to proteins which are present as the contaminants in the process. 
This preferential flocculation is due to the active hydrophobic surface differences on 
viruses and protein surfaces. We studied the effect of membrane pore size on the 
recovery of viruses and were able to achieve 60% recovery of infectious PPV using a 0.1 
µm and 500 kDa pore size filters. Recovery of infectious SINV was 79% using 0.1 µm 
and 96% using 500 kDa pore size membrane filter. Increasing the concentration of virus 
results in enhanced recovery of infectious particles, but at high concentration, membrane 
pores can get blocked, causing membrane fouling. We also examined the purity of the 
recovered virus samples for DNA and protein contaminants. In conclusion, we have 
developed a novel purification process that was able to purify and recover infectious viral 
particles using large pore size filters, which can decrease overall processing costs. 
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1. Introduction 
Infectious diseases have caused an enormous death toll worldwide over the last 
century. Viral pathogens cause many of the infectious and severe diseases. HIV/ AIDS 
causes 1.6 million deaths every year, and about 36.9 million people are living with the 
illness according to the World Health Organization [1]. Vaccines are the best tool to fight 
against many viral diseases and can help prevent millions of deaths. According to the 
WHO, by 2020 the Global Vaccine Action Plan (GVAP) [2] calls for more equitable 
coverage of basic existing vaccines to all communities in the world. These plans are 
focusing on increasing current vaccine manufacturing capacity and creating new 
manufacturing units in developing countries like India and China. This will be done in 
partnerships with the Developing Countries Vaccine Manufacturers Network (DCVMN) 
and Global Alliance for Vaccines and Immunization (GAVI) [3]. They will be focused on 
finding cost-effective vaccine manufacturing process. The findings from this work will be 
able to contribute in research and development for alternative platforms in downstream 
processing of vaccine manufacturing. A platform approach for vaccine production can be 
a fixed setup and technique for downstream processing that can be applicable to various 
types of vaccines with minimal changes in the process and protocol.  Downstream 
processing deals with the recovery and purification of target viral product for vaccine 
formulation. 
Recent techniques used in vaccine downstream processing are using traditional 
methods such as the combination of several chromatographic steps and ultrafiltration for 
the purification of viral products [4]. Chromatographic methods have been used for 
proteins and other biological products and are not properly optimized for large biological 
molecule purification, like viral products. Ultrafiltration method uses small pore size 
membranes that often foul and has a significant pressure drop, which increases 
processing cost. In a typical purification process, more than 75% of total production cost 
is from downstream processing [5]. Therefore, developing a low-cost platform 
downstream process could substantially reduce the cost of a vaccine product. We propose 
an alternative approach to chromatography or ultrafiltration, using microfiltration to 
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reduce the membrane cost and the required pressure for filtration. We also plan to apply 
this novel process to many different virus types so that this platform approach can be 
applied to multiple viral products. 
In this work, we have used a novel osmolyte flocculation method, which was 
demonstrated in our lab’s previous research publications  [6, 7]. This flocculation study 
has shown that we can flocculate viruses using naturally occurring compounds known as 
osmolytes, which are found naturally in many organisms. After screening several 
osmolytes, Gencoglu et.al showed that the osmolyte mannitol was able to flocculate the 
model viruses PPV and SINV and was able to remove >80% of the infectious virus 
particles with a 0.2 µm filter [6, 7]. The osmolyte mannitol has been FDA approved to be 
used in human therapeutics or as the therapeutic agent. Mannitol 20% injection USP drug 
is being used as osmotic diuretic for certain kidney conditions, brain damage for reducing 
swelling and pressure in brain and eyes [8, 9]. Therefore, as it is naturally occurring and 
FDA approved, complete removal of mannitol in the downstream processing is not a 
concern. In continuation to this previous study from our lab, we are developing a 
downstream processing platform for purification and recovery of viruses using a 
diafiltration method. 
This thesis begins with a brief background and motivation for these studies.  Chapter 
2 is the literature review, giving background for viral diseases and vaccines, current 
vaccine manufacturing method and motivation and rationale as to why we are looking for 
new approaches. In chapter 2, we demonstrated how this scientific study is needed and 
can contribute to the need for faster and less expensive vaccine manufacturing platforms. 
Chapter 3, contains experimental details and materials used for all experiments. 
Chapter 4 shows the results for all experiments with different parameters for PPV and 
SINV virus removal, stating results, findings and a discussion of this research. Chapter 5 
has the concluding comments about the overall research and includes proposed future 
work, which can shed more light on the osmolyte flocculation mechanism.  
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In this research, we have shown recovery and purification of PPV and SINV. First, 
by studying the effect of different membrane pore size for recovery of viruses, we found 
that using larger pore size membrane of 0.1 µm can give 60% recovery of infectious PPV 
while decreasing the pore size results in increased recovery. Using diafiltration for PPV 
we demonstrated purification of viruses in the retentate from host proteins using HPLC 
analysis.  We also explored the effect of flocculation time and initial virus concentration. 
We have found that using high concentrations of viruses can optimize the recovery of 
infectious virus particles, but the high concentration of viruses can lead to membrane 
fouling and can increase the pressure requirements for filtration. We analyzed recovered 
PPV samples for purity, and we are able to remove 85% contaminant proteins for 
purification and only 45% DNA content removal was observed. 
For SINV recovery, we compared all parameters listed above for their effect on 
recovery of infectious virus particles. Using a large pore size of 0.2 µm gives a 65% 
recovery and using a 0.1 µm filter gives 79% recovery. For the purification of SINV, our 
current analysis showed only 37% removal of protein contaminant and 49% DNA 
removal. Future work will focus on increasing removal of DNA using additional 
treatments. All presented results show flocculation of virus particles and recovery of 
infectious virus particles using large pore size membranes. These findings show promise 
that mannitol flocculation can be applied within the industry to provide low-cost 
downstream processing which is safe and scalable. 
 4 
2. Literature Review 
2.1. Viral Diseases, Viruses, and Vaccines 
Infectious diseases have, and continue to be, a major threat to public health. 
Emerging infectious diseases has threatened human health throughout the history of 
humankind. Infectious diseases are caused by the bacteria, viruses, parasites or various 
fungi [10]. Viruses cause many diseases that are fatal to their host. Some of the common 
viral human diseases and their global effect are shown in Table 2-1. 
Table 2-1 Infectious diseases and effects worldwide, [1] 
Disease Virus Effect 
Measles Paramyxovirus 114,900 measles deaths globally 
about 314 deaths every day or 13 
deaths every hour (2014) 
AIDS Human 
immunodeficiency virus 
1.2 –1.6 million deaths every 
year (2014) 
Hepatitis B Hepatitis B virus 780,000 people die every year 
Ebola haemorrhagic 
fever 
Ebola virus Worldwide 28,646 cases of Ebola 
virus disease and 11,323 deaths 
Dengue and severe 
dengue fever 
Dengue virus and 
serotypes 
390 million dengue infections per 
year 
Influenza A(H1N1) 
and A(H3N2) 
subtypes 
Influenza virus and 
serotypes 
3 to 5 million cases of severe 
illness, and about 250,000 to 
500,000 deaths annually 
 
Viruses are pathogens which can replicate only inside the cells of living host 
organisms [11]. Viruses can infect all types of organisms such as human, animals, plants 
and bacteria. Reports show that there are about 5000 different types of viruses that have 
been described at current times, and there could be millions more that we are not yet 
aware of [12]. Viruses are typically very tiny, although they range from a few nanometers 
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to a micron in size. The smallest known virus is porcine circovirus, at around 17 nm in 
diameter and porcine parvovirus about 20-24nm [13-15]. Other viruses are larger than 
some bacteria such as vaccinia virus (230 nm), mimivirus (500 nm) or Pandora virus 
(about 1 µm)  [12, 15].  
Viruses are categorized mainly by their outer layer structure and nucleic acid 
content. For the nucleic acid content, viruses encapsulate either DNA or RNA genetic 
material [12, 16]. Depending on the genome content of viruses, viruses are classified as 
RNA viruses and DNA viruses. RNA viruses comprise about 70% of all the viruses and 
can contain single-stranded (ssRNA) or double-stranded (dsRNA) viral content [17].  
Depending on the outer layer structure of viruses can be divided into enveloped and 
non-enveloped viruses. The encapsulated nucleic acid genome contains a protective 
protein layer which forms the capsid [16]. If the virus contains an outer lipid bilayer 
membrane around the virus protein capsid, they are called enveloped viruses. This outer 
lipid layer around enveloped viruses contains viral proteins which help in binding to the 
host cells. Whereas viruses which do not have outer lipid layer are called non-enveloped 
viruses. In the case of non-enveloped viruses, the function of binding to the cells is 
carried out by the capsid proteins [18]. Due to the large chemical differences in the outer 
layer of the virus, developing a processing method which can be applied to different 
types of viruses is an important aspect of developing a platform downstream processing 
approach. 
One of the most efficient methods to date to combat viral diseases is through 
vaccines [19], and vaccines are best accomplishments through science for the benefit of 
public health [20]. Viruses which causes infectious diseases can be used to fight against 
diseases in the form of viral vaccines. The goal of the vaccines is to help the human body 
to form immunity against a viral infection by producing an antibody response [21]. This 
allows the body to fight against the virus when the body encounters it, before the 
infection taking hold in the body. During 2000-2014, measles vaccination prevented 17.1 
million deaths. Polio cases from the world have been decreased by 99% because of 
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vaccines. Influenza vaccines save millions of people from high influenza complications 
and can provide reasonable protection in adults upon vaccination worldwide [1]. 
The first vaccine by Edward Jenner for smallpox was able to eradicate smallpox [22, 
23]. Also, the first attenuated vaccine developed by Louis Pasteur for rabies by 
attenuating rabies virus in the laboratory [24]. Discovery of the first vaccine was the 
landmark achievement as it shows that using the virulent virus as a vaccine can help to 
fight against the disease. Since Jenner’s discovery and Pasteur’s vaccine, the advances in 
immunological studies have helped us to understand how the immune system can help to 
fight against diseases using vaccines [22, 23]. There has been continuous research going 
on to find improved technology for improving quality and quantity of vaccine production. 
Even with all the recent advancement in immunology and vaccine manufacturing, there is 
no equality in distribution and availability of vaccines in industrialized developed 
countries as compared to developing and poor countries [25]. The current global 
vaccination plans focus on the public health within developing and poor countries which 
requires wide and easy access to large quantities of vaccines at affordable cost. One of 
the major strategic goals of the WHO includes more focus on the research and 
development in vaccine manufacturing in developing and middle-income countries [2]. 
There are about 22 millions of children in poor and developing counties which are still 
not protected against viral diseases due to lack of vaccination availability [26]. Global 
coverage for basic vaccines shows that there is need of a major supply of vaccines needed 
in south-east Asia, Western Pacific region and African region. Figure 2-1 shows the 
global coverage of current basic vaccines. Out of this total global coverage for vaccines, 
Table 2-2 shows the areas affected most by low coverage of immunization. 
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Table 2-2 Global vaccine coverage by April 2015, [1] 
 
WHO along with DCVMN and GAVI are working together to provide access to 
vaccines in poor and developing countries like India, China, and the African Union. So, 
emerging and developing countries are looking for affordable vaccine manufacturing 
processes so they can start their own vaccine production units [27]. 
 
Figure 2-1 Global immunization coverage WHO [1] 
 
Unlike other chemical drugs, vaccines are made from biological agents which are 
susceptible and can be compromised during various manufacturing processing stages. At 
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every stage of vaccine processing, it needs strict regulations for safety and quality 
monitoring in the manufacturing. There are various regulatory authorities for maintaining 
regulations for vaccines such as Food and Drug Administration’s (FDA) Center for 
Biologics Evaluation and Research (CBER) in the United States, the European Medicines 
Evaluation Agency on behalf of WHO, and the National regulatory authority (NRA). The 
regulatory agencies focus on safety, efficacy and purity. In the exploration of new virus 
purification methods, the regulatory restrictions on safety, efficacy, and purity must be 
kept in mind. 
We are pursuing methods to reduce the cost of viral vaccine manufacturing so that 
distribution to GAVI countries can be greatly increased.  The focus of our research is to 
create an economical vaccine manufacturing processes using FDA approved osmolytes as 
preferential flocculants while keeping the regulatory requirements of safety, efficacy and 
purity in perspective as a platform approach. Also, the approach should not be limited to 
lab scale and should be easily scalable for large scale production. Our goal is to establish 
a low-cost vaccine manufacturing process so that vaccines can be available at reduced 
rates in poor and developing countries. 
 
2.2. Types of Vaccines 
Traditional vaccines contain part or all of a disease-causing agent. Many of the 
vaccines are based on viruses.  There are three main types of vaccines, live/attenuated, 
inactivated and subunit vaccines. There is a sense of balance between protection and 
efficacy when choosing which vaccine type to pursue. 
Live attenuated vaccines contain the whole viruses in an attenuated form which are 
weakened by passing through multiple cell cultures so that it cannot cause a serious 
disease in humans. They provide a strong immune response against the disease and can 
provide lifelong immunity with one or two doses. Live attenuated vaccines are successful 
against human viral diseases, however as this vaccine type contains live viruses that are 
very similar to the natural infectious virus, there can be some safety issues. Live 
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attenuated vaccines can become virulent or mutate at some point and cause the disease [3, 
28]. There have been cases reported about live attenuated polio vaccine which was found 
to contain wild-type polioviruses [28, 29]. Report from 2009 showed that the polio 
vaccine paralyzed several children in 2007, 2008 and 2009 [1].Therefore, the quality and 
purification processing during live vaccine manufacturing is critical to minimize the 
downsides of live vaccines. The examples of live attenuated vaccines are measles, 
mumps, rubella (MMR combined vaccine), rotavirus, varicella (chickenpox), influenza 
(live attenuated influenza vaccine) [30]. Also one of major limitation with the live 
attenuated vaccine is storage, as these vaccines need to be refrigerated to keep the 
potency and effectiveness. This leads to a higher cost vaccine. Developing countries and 
poor countries lack widespread refrigeration. So, considering these are important factors, 
manufacturers from developing countries are looking to manufacture vaccines in their 
own region so it will minimize the cost of vaccines and avoid shipping overseas from 
other countries.  
Inactivated vaccines are produced by using viruses that cannot replicate due to 
chemical, heat or radiation inactivation methods [31]. Inactivated vaccines typically 
create a weaker immune response than live attenuated vaccines, so inactivated vaccines 
are given in several dosages or booster shots may be required to keep immunity against 
the disease [32]. The high number of dosages leads to high immunization costs in areas 
where there are no health care facilities available, specifically in poor and developing 
countries. Inactivated polio (IPV) and hepatitis A (HAV) are examples of inactivated 
vaccines [33].  
Instead of using the whole virus for vaccines, subunit vaccines contain only part of 
an antigen from the virus, which activates an immune response against it. Subunit 
vaccines are typically expressed recombinantly in bacterial cells, decreasing the cost and 
complexity of manufacturing, as compared to mammalian or insect cells that are needed 
for live-attenuated and inactivated vaccines [32]. Hepatitis B, influenza (injection), and 
haemophilus influenza type b (Hib) are examples of subunit-conjugate vaccines [33, 34]. 
As inactivated vaccines may need several dosages, it may be challenging to provide 
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vaccination in the areas where people do not have continuous access to health care 
services and are unable to get all the dosage or booster shot in a timely fashion [35]. 
2.3. Model Viruses 
To study viral purification and virus recovery and propose a universal platform that can 
be applied to all types of viruses, we need to select suitable types of viruses which can be 
a good model for viruses used as human therapeutics. There are two major types of 
viruses, enveloped and non-enveloped viruses. Non-enveloped viruses do not contain an 
outer phospholipid coating; there is only a protein capsid that surrounds the viral nucleic 
acids. Enveloped viruses contain an outer envelope around the viral capsid which is made 
of phospholipids and proteins or glycoproteins [36]. We wanted to study both types of 
viruses, i.e. enveloped and non-enveloped virus as presence or absence of envelope can 
affect the flocculation studies significantly. 
For our virus purification study, two viruses were selected as models; the non-
enveloped PPV and the enveloped SINV. Parvoviruses cause the variety of diseases in 
vertebrates and arthropods and have been isolated from mammals like humans, dogs, 
cats, rodents, cows, and pigs [37]. Parvoviruses are the second smallest known 
mammalian virus at 18-26 nm in diameter and contain single-stranded DNA [13, 14]. 
PPV is a common cause of reproductive failures in swine [38]. PPV is a good model 
virus for human B-19 parvovirus, hepatitis A, and poliovirus. B-19 parvovirus is 
widespread in human and causes erythema infectiosum skin rash illness and it is more 
common in children than adults (CDC) [39]. We use PPV as a model virus because it is 
small, making it difficult to separate by using size-based methods and represent non-
enveloped, DNA virus type. PPV is resistance to heat and is chemically inert as it shows 
resistance to physical or chemical treatment [40-42]. 
Our enveloped virus model, SINV, is an arthropod-borne virus from the Togaviridae 
family [15]. It is a single-stranded RNA virus with an icosahedral capsid and contains a 
protein envelope made of glycoproteins. SINV causes epidemic polyarthritis and rash 
sickness commonly known as Pogosta diseases in humans which may lead to prolonged 
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arthritis [43]. SINV is one of smallest enveloped virus with size about 50-60nm [14, 44]. 
SINV is a model virus for eastern and western equine encephalitis viruses which causes 
infection in human and horses and are widespread deadly diseases. As it contains an outer 
envelope layer, surface properties of SINV such as hydrophobicity and charge play a 
major role in different purification methods.  
As successive research in virus purification with various viruses has provided the 
detailed understanding of the viral structures and how properties of viruses such as size, 
isoelectric potential (pI), virus hydrophobicity, and the presence of envelope can alter 
purification processes [4, 45]. Viruses possess a pH dependent surface charge in polar 
media such as water or buffer. This surface charge determines the absorption of virus 
particles on surfaces, and it can govern the colloidal behavior of viral particles [46, 47].  
One measure of colloidal charge is the isoelectric point (pI). The pI is the pH at which 
surface charge changes its sign or acts as a neutral molecule. The isoelectric point (pI) for 
PPV is about 5.5 [48], and the pI for SINV is about 4.4 [49].  
For our studies for flocculation with osmolytes, the hydrophobicity of viruses is an 
important property as flocculation is hypothesized to be based on the preferential 
hydration and hydrophobicity difference between viruses and proteins [6, 7]. 
Hydrophobic interactions are the forces between two non-polar groups which attract two 
particles together. Non-polar molecules tend to form intermolecular contacts to reduce 
their surface contact with polar molecules, such as water. In the case of our hypothesis, 
viruses are hydrophobic in nature and contain water shell around outer surface in an 
aqueous solution. Upon removing the water surrounding the virus particles with 
osmolyte, viruses tend to attract each other and forms aggregate. This effect is explained 
on proteins by C.J. VanOss, 1995 through precipitation of proteins by dehydration 
method. By removing water around particles, their surface at the interface becomes more 
hydrophobic. This changes the normal repulsive forces between particles and turns them 
into the net attraction forces causing particle aggregation [50]. Studies in the literature 
have shown the presence of hydrophobic areas on the virus surfaces.  
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Both enveloped and non-enveloped viruses contain sites for fusion proteins on their 
outer surface which helps the attachment to the host cell membranes. In the study by 
Badani et al. 2014, it was shown that viral fusion proteins or viral membranes contain 
hydrophobic segments. It has shown virus attachment to the host cell is related and driven 
by the hydrophobicity of viral binding proteins or viral membrane surface [51].  As per 
their hypothesis, the virus entry inhibition is explained by the physical chemistry of 
hydrophobicity i.e. active hydrophobic sites and patches on different sites of virus surface 
(e.g. class I, class II and class III fusion proteins on viruses) on the viruses as well as on 
the cell membranes. The Wimley–White interfacial hydrophobicity scale is used to 
determine the hydrophobicity range based on the interfacial hydrophobic interactions 
[52]. This method determines the transfer free energy of the amino acids along with 
peptide sequence. The transfer free energy is a scale of the propensity for amino acids to 
transfer from water to phosphatidylcholine interface [51]. Badani et al. used this Wimley-
White interfacial scale to score hydrophobicity based on interfacial hydrophobic 
interactions of viruses. On this scale, a positive score indicates the presence of 
hydrophobic interaction based on peptide sequence and hydrophobic interactions. Zero 
point on scale divides the peptide sequence regarding free energy into hydrophobic or 
not. They have shown positive scores for Dengue virus, West Nile virus, murine hepatitis 
virus, respiratory syndrome coronavirus, influenza virus, hepatitis C virus [51]. This 
demonstrates that viruses have active hydrophobic sites present on their surface. This 
study was showed for all enveloped viruses. Another study has shown the presence of 
hydrophobic sites on non-enveloped Reovirus membrane [53]. 
Our past work on PPV concluded that both hydrophobicity and charge play a major 
role in the binding of porcine parvovirus, and we have shown that viruses are more 
hydrophobic than proteins thus hydrophobicity of viruses plays an important role in 
flocculation of viruses using osmolyte [6, 7].  
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2.4. Vaccine Manufacturing  
Current manufacturing methods for vaccines, related therapeutics, bioproducts are 
very product specific. Traditionally, vaccines were prepared using embryonated chicken 
eggs or animals. For example, Edwards Jenner’s first vaccinia was inoculated in cows 
[22, 23]. More recently, the seasonal flu vaccine is prepared using fertilized embryonic 
eggs, which usually takes a long time to prepare [54].  Egg-based methods are a labor 
consuming method, requires a significant amount of fertilized eggs at one time and is 
highly susceptible to bacterial contamination. Additionally, individuals that are allergic to 
eggs may not receive this type of vaccine. 
Since the development of new methods and research in vaccine manufacturing, cell-
based vaccine manufacturing processes are being used to produce vaccines. Cell-based 
vaccine manufacturing was first done by using in vitro cultivation with non-neural human 
cells by Enders in 1949 for poliovirus and then in 1955 by Salk for inactivated polio 
vaccine using monkey kidney cells [55]. From that time, industries are significantly 
looking to use cell culture-based vaccine production using mammalian cells.  Cell culture 
based vaccine manufacturing methods can be much safer, as processing takes place in 
closed systems, the chances of contamination are reduced [56]. The vaccine regulatory 
authorities encourage cell culture based vaccine manufacturing and this method can be 
scaled up for emergency large production requirements. The production time for cell 
culture-based vaccine manufacturing is reduced to half as compared to traditional vaccine 
manufacturing using embryonic eggs based method [54]. However, using cell culture-
based vaccine manufacturing produces less virus, and the volumetric yield is low [54]. 
This requires large volume bioreactors to achieve the desired yield of viruses, which adds 
up to higher capital investment for the production plant. The relatively higher 
manufacturing cost may translate to more expensive vaccines. New research and 
development teams are focusing towards developing current vaccine manufacturing 
processes so that the cost of manufacturing and vaccines will be more economical. Our 
focus is to develop alternate low-cost vaccine manufacturing platforms to create an 
economic vaccine manufacturing process.  
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2.4.1. Upstream and Downstream Processing 
Vaccine manufacturing process is classified into two different stages, upstream and 
downstream processing, as shown in Figure 2-2. Upstream processing comprises of 
growing and cultivation of cells, infecting the cells with the virus of interest and 
harvesting of cell lysates. Once cells are infected completely, and viruses are reproduced, 
cell lysis is typically performed through homogenization or adding non-ionic detergents, 
like Triton X [57, 58]. Next, cell debris is removed through clarification, which can be 
carried out with centrifugation, or filtration methods [59-61]. Once the clarified solution 
is obtained, it proceeds to downstream processing, involving purification, concentration, 
and polishing. 
 
 
Figure 2-2 General outline for Vaccine manufacturing with upstream and downstream processing, 
upstream processing includes cell growth, virus production, and downstream processing deals 
with clarification, purification, and recovery of viruses. 
After harvesting viruses from the host cells, downstream processing deals with the 
purification and concentration of the viral products. Purification is aimed at removing 
contaminating host cell proteins, DNA, and impurities introduced during the purification 
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process. Using a variety of physical properties as size, isoelectric potential (pI), and the 
hydrophobicity different methods are selected for purification [4, 45]. There are several 
methods for virus purification. Commonly used methods for virus purification are 
ultrafiltration and chromatography [4, 62-65]. Membrane-based ultrafiltration is typically 
used for partial purification and chromatography is usually used for final product 
purification. Other purification methods are depending on the viral size and properties 
such as ultracentrifugation which uses density based separation, precipitation by 
chemicals, PEG, flocculation using salts, and membrane absorption which uses charge 
based properties of viruses [60, 66-69]. 
2.4.2. Ultracentrifugation 
One of the methods employed for virus purification is ultracentrifugation. Density 
gradient centrifugation using cesium chloride or iodixanol gradient is one of the well-
known and established method for the virus in preclinical studies [4, 66, 70]. Also, there 
are concerns over CsCl toxicity and its complete removal after viral purification can be 
challenging. While ultracentrifugation leads to very pure products, the lack of scale-up 
options makes it undesirable for manufacturing. This method can be used for limited 
sample separation by using ultracentrifugation, which uses very high rotational speeds.  
The purification is based on the different buoyant densities of virus particles and 
contaminants. Ultracentrifugation will even separate full from empty viral particles [71, 
72]. This method is mostly used in a lab due to the lack of industrial scale 
ultracentrifuges. A CsCl density gradient was used for the purification of adenovirus (Ad) 
and adeno associate virus (AAV) [66, 73], showing lab-scale purification for Ad and 
AAV. A recent study showed a 60% yield for CsCl and a 65% infectious units recovery 
for an iodixanol based AAV purification method [74]. While yield and purity can be high 
with ultracentrifugation, the lack of scale-up options makes it unfeasible for vaccine 
production. 
2.4.3.  Chromatography 
In the biopharmaceutical industry, chromatography is the most commonly used 
separation and purification technology due to its easy applications to all products and its 
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high resolution. Chromatography separation is based on the different interactions 
between viruses and the surface of chromatographic beads such as size based (size 
exclusion chromatography), charge based (ion exchange chromatography), and 
hydrophobicity based (hydrophobic interaction chromatography HIC, reverse phase 
chromatography). Ion exchange chromatography is charge based separation depending on 
the interactions between charged particles and ionic ligands on the chromatography 
beads. Therapeutic molecules bind to the column under low salt condition and elution is 
done using high salt gradient because the ionic interaction is disrobed by the high ionic 
strength solution. Hydrophobic interaction chromatography is based on binding of 
particles to the hydrophobic surfaces depending on the hydrophobicity of particles. In 
HIC, particles are loaded in the high salt buffer which promotes the hydrophobic effect 
and drives adsorption with solid support. The separation works with low salt gradient 
based on the difference in hydrophobicity as a result of desorption from resin. 
Several studies have shown that various chromatography methods such as ion 
exchange, size exclusion chromatography, affinity chromatography in combination with 
multiple chromatographic steps in series or with membrane filtration can be used for 
virus purification and recovery [64, 75, 76]. Bead chromatography methods have a high 
surface area in the internal pores of the beads, and the capacity of the resin subject to the 
diffusion of molecules into the pores of the beads. This poses a big limitation for the 
purification of large molecules that either cannot enter the pores or quickly plug the pores 
upon binding. One newer method to overcome the problem of bead chromatography is 
membrane chromatography. In membrane chromatography, all of the surface area is 
accessible by convective flow and does not rely on diffusion into pores [77]. This allows 
for the much more accessible surface area by large biomolecules. However, there is still 
low overall surface area per volume with membrane chromatography. It has therefore not 
been implemented as much as originally thought. In Table 2-3, we have shown some of 
the work which uses the chromatographic technique as primary purification method with 
or without the combination of other methods. 
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Table 2-3 Literature review for some of the chromatographic techniques used in purification of 
viruses 
Study Method Results Reference 
3 step chromatographic 
process for Influenza type 
A & B purification 
Anion exchange chromatography, 
benzonase treatment and final size 
exclusion chromatography 
68% virus yield and 
98% DNA removal 
[78] 
Purification of Rotavirus- 
like particles (RLP’s) 
using chromatography 
Anion-exchange membrane 
chromatography 
46% global yield, 
100% DNA removal, 
98% HCP removal 
[75] 
Purification and 
characterization 
(immunogenicity) of 
norovirus (NoV) VLPs. 
Anion exchange chromatography 
Retained immunogenicity 
(immunoblotting) 
Final yield is not 
mentioned, 90% 
purification w.r.t. 
DNA content and 
HCP 
[79] 
Combined ultrafiltration 
and chromatography 
process for Porcine 
reproductive and 
respiratory syndrome 
virus (PRRSV) 
Ultrafiltration using 300,000 
nominal molecular weight limit 
(NMWL) membrane followed by 
heparin affinity chromatography 
54% final PRRSV 
recovery, 96% 
cellular and medium 
proteins removal 
[80] 
Recovery of porcine reproductive 
and respiratory syndrome (PRRS) 
virus using ultrafiltration and anion 
exchange chromatography 
50% recovery of 
PRRSV 
[65] 
Purification of 
Adenovirus using 2 step 
anion exchange 
chromatography 
Set of 2 anion exchange 
chromatography (1st Q Sepharose, 
2nd Source 15Q) 
40% infectious unit 
recovery of 
Adenovirus and 99% 
purity 
[81] 
Purification of 
Adenovirus using 
combined 
chromatography 
technique 
Primary purification using anion 
exchange chromatography and final 
polishing using size exclusion 
chromatography 
80% virus particles 
recovery, 99% purity 
[82] 
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Influenza A virus 
recovery and purification 
using 2 chromatography 
steps 
Size-exclusion chromatography 
(SEC) and anion-exchange 
chromatography 
Final product yield of 
52%, and 19-fold 
HCP reduction, 500-
fold DNA content 
reduction 
[83] 
 
As discussed earlier chromatography offers advantages for high purification and 
product yield but it has several disadvantages. Chromatography is mainly used for protein 
purification and has been adapted for virus purification. There is no platform 
chromatography method which can be used for viruses because of different structure, 
size, and charges of viruses. Also, the concentration of viruses cannot be done solely 
using chromatographic technique [84]. So there is a need for downstream processing to 
look for new platform approach other than using chromatographic techniques for viral 
vaccine processing. 
 
2.4.4. Filtration 
Filtration has been an integral part of biotechnology, and it is used as both a 
concentration and separation method for viral products [68]. Membrane based separation 
and purification methods are typically applied as size-based separations. This approach 
can provide good separation and purification and is easy for scaling up at commercial 
scale with high throughput. Current membrane based separation methods typically use 
ultrafiltration membranes. Diafiltration using ultrafiltration membranes has been widely 
used in virus DSP for concentration and separation as described in the literature [68, 85, 
86]. Ultrafiltration membrane range in pore size from 0.5 to 1000 kDa MWCO [87]. 
Filtration methods can be operated in two types of flow, normal flow filtration (NFF) 
(also called dead end filtration) and tangential flow filtration (TFF). In NFF, flow is 
perpendicular to the membrane and particles larger than the membrane pore size are 
typically withheld by the membrane, while smaller particulates pass through the 
membrane. This mode is usually used when the product of interest passes through the 
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membrane. This is because the larger size particles are retained on the top, causing a 
buildup of particles on top of the membrane, which leads to cake formation on the 
membrane, increased sieving and increased transmembrane pressure  [88, 89]. To avoid 
this, TFF uses the tangential flow of fluid with applied pressure. As in NFF particles 
larger than pore sizes are retained and smaller particulate pass through the membrane, 
while tangential flow sweeps the retained particles to avoid buildup on the membrane. In 
operation of TFF, once a steady-state is reached, the transmembrane pressure stays 
relatively stable. Membrane-based TFF is applicable in downstream processing of many 
biologics and viruses. Low pressure and cross-flow pattern of TFF with hollow fiber 
membranes provide less stress on particles than dead end filtration and promotes gentle 
treatment for virus particles and proteins to retain their structural activity [5]. However, 
there is still possibly a flux decline due to fouling and shearing of the particles, which 
could cause virus inactivation. To avoid this disadvantages using membrane-based 
separation method, we are looking at the combination of flocculation and membrane 
filtration methods so that we can use large pore size membranes for virus purification and 
recovery.  
TFF using the ultrafiltration membrane for concentration and purification is one of 
the most common purification steps before or as a final polishing step [90-93]. It was 
shown that the membranes with smaller pore sizes than the virus particles can be used for 
concentration and purification of viruses [92]. Using small pore size ultrafiltration 
membranes for virus/ viral vector recovery was performed in several studies as shown in 
Table 2-4. 
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Table 2-4 Tangential flow filtration studies for various virus/ VLP/ vectors from the literature 
Study Virus Size Method, Results Reference 
HIV-1-derived 
lentiviral vector 
80-130 nm TFF (300 kDa), 100% recovery 
TFF (100 kDa), 100% recovery 
TFF 100 kDa+ 5 hour centrifugation 26000g, 18% 
recovery* 
TFF 100 kDa+ 2 hour centrifugation 76000g, 94% 
recovery* 
* transducing units recovery after centrifugation 
[90, 94] 
Aedes aegypti 
densonucleo- 
Sisvirus 
20-30 nm TFF using ultrafiltration membranes, 30 kDa and 50 
kDa able to retain virus particles while using 100 
kDa and 300 kDa particles can be seen in permeate 
[91, 95] 
Influenza A 
virus (Human 
virus Type A) 
80-120 nm Screening of ultrafiltration membranes100 kDa, 300 
kDa, and 0.1 μm, 0.2 μm MWCO membranes, 
results showed 300 kDa membrane gives optimal 
recovery and 84% protein removal 
[92] 
Flavivirus 
pseudoinfectious 
virus  
40-60 nm 2 step purification method with TFF (using 100 kDa 
and 500 kDa TFF cassette) followed by anion 
exchange chromatography. TFF with 100 kDa gives 
recovery 80% followed by 54% recovery in AEX 
[96, 97] 
Parvovirus 
Minute Virus of 
Mice 
22-26 nm Purification and recovery using high-performance 
tangential flow filtration, optimal virus exclusion 
observed with 50 kDa and 100 kDa membranes, 300 
kDa membrane not effective in retaining virus 
particles 
[98] 
HIV VLP 120 nm Recovery and concentration of HIV VLPs using 500 
kDa hollow fiber on automated TFF system 
[99] 
Viral 
adventitious 
agents (AAs) 
Adenovirus 
70-90 nm, 
Parvovirus 18-
26 nm, 
Herpesvirus 
110 nm, 
Simian virus 
45 nm 
Large scale (500 liters) recovery and concentration 
of 4 viruses using 100 kDa MWCO hollow-fiber 
filters: 
Human adenovirus type 5, 84 % recovery 
Bovine parvovirus, 93 % recovery 
Bovine herpesvirus 4, 85 % recovery 
Simian virus 40, 88 % recovery 
[100] 
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These studies have shown using ultrafiltration membranes of size ranging 30kDa to 
100kDa can be utilized for purifying viral particles based on the size of particles. 
Optimum recovery was shown in the retentate while removing host cell proteins. Pore 
plugging due to pore size variability in membranes, plugging of proteins, small viral 
fragments reducing the flow rate, declining membrane reflux, and requirements of high 
throughput pressure system is shown in many studies [91, 96, 98, 99]. As described 
above regarding the current ultrafiltration methods, to overcome challenges 
microfiltration can be a better option. As disadvantages of ultrafiltration add up to high 
processing cost as the high-pressure system is required. Also, it can increase the 
processing time and membrane washing steps are required, and there will be reduced 
flow rate [101]. We are using large pore size membranes which will eliminate this 
challenges and will be able to provide a cost effective method. 
 
2.4.5. Precipitation and Flocculation 
Precipitation is commonly used method for protein concentration [102]. It is 
typically performed by the salting out of proteins with the high concentration of salts 
such as ammonium sulphate ((NH4)2SO4) or sodium sulphate (Na2SO4) [102, 103]. 
Precipitation by polyethylene glycol (PEG) has been used for virus concentration and 
purification for viruses such as murine leukemia virus [104] and influenza virus at a low 
concentration of PEG [105]. Several PEG-based precipitation experiments have shown 
that PEG precipitates proteins [106-108] when used at greater than 5% concentration. 
Therefore, higher PEG concentrations can concentrate, but not purify virus. While lower 
concentrations of PEG can purify virus by precipitating virus and not proteins, salt 
precipitation can precipitate proteins and can affect the virus integrity [102]. Flocculation 
using polyaluminum chloride has shown flocculation of bacteriophages due to influence 
on the surface characteristics of phage particles, but this method also affects viral activity 
and shows inactivation of bacteriophages [109]. This flocculation in the presence of 
polyaluminium chloride happens because at that pH the surface charge of phages 
becomes neutral and electrostatic forces becomes insignificant which drives particles to 
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aggregates. The study for selective precipitation of Immunoglobulin G (IgG) and proteins 
showed that different concentration of ammonium sulfate for precipitation. The 
Concentration of 2.5 M ammonium sulfate found to precipitate bovine serum albumin but 
not IgG [110].  Table 2-5 shows some methods from literature for precipitation of 
viruses. 
Table 2-5 Various precipitation method used for purification and recovery of viruses 
Virus Precipitation method Reference 
Ocean Viruses Recovery using FeCl3 flocculation method with 
tangential flow filtration, 90% recovery. 
[111] 
Enterovirus & 
MS2 
bacteriophage 
Recovery using ammonium sulfate (low pH 3.5) 
precipitation method with centrifugation, 70% 
enterovirus recovery, 84% bacteriophage recovery. 
[112] 
Recombinant 
VLP from yeast 
homogenate 
Recovery and purification PEG precipitation (PEG 
6000) using centrifugation,  
90% recovery in sediment 
[113] 
Bacteriophage Purification using salt precipitation with MgSO4, 
NaCl, and PEG 
PEG 6000+ NaCl: 92% recovery 
PEG 6000+ MgSO4: 91% recovery 
[102] 
PPV Virus removal using osmolyte mannitol and alanine 
flocculation method followed by microfiltration, 80% 
removal of PPV 
[6] 
SINV Virus removal in the presence of osmolyte mannitol as 
flocculating agent and removal using microfiltration, 
96% removal of SINV with mannitol 
[7] 
 
Precipitation or flocculation is typically followed by centrifugation or filtration to 
either remove or recover the flocculated/precipitated species. Flocculation prior to 
filtration is highly desirable as it can reduce the membrane fouling, increase product 
recovery and decrease the number of steps for final product purification [114, 115]. 
While in Table 2-5, it is shown that FeCl3, MgSO4, NaCl, and PEG have been used for 
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the flocculation of viral products, previous work in our lab has demonstrated that a class 
of natural compounds called osmolytes can flocculate virus particles without affecting 
proteins. 
Our lab’s previous studies have explored a variety of osmolytes for flocculating the 
model non-enveloped and enveloped viruses, PPV and SINV [6, 7]. Different osmolytes 
and concentrations were screened for their ability to flocculate and remove the virus with 
a 0.2 µm filter. The osmolytes mannitol, alanine, glycine, trehalose showed the removal 
of PPV of greater than 80% (Figure 2-3-A). Comparing the size of the virus, which is 
about 20 nm, to the 0.2 µm filter, this results supports the hypothesis that the osmolytes 
can flocculate virus particles.  For the enveloped virus SINV, mannitol, glycine, betaine, 
and proline were able to remove >80% of the virus with a 0.2 µm filter (Figure 2-3-B).  
Mannitol was able to remove 98% of the SINV in solution.  
Studies were carried out to conclude the effect of ionic strength and pH on the 
removal of PPV and SINV. Increasing the ionic strength of solution by addition of salt 
0.2 to 0.6 M NaCl to 1M mannitol decreased the PPV removal, possibly because the 
addition of salt affected the viscosity of the solution, decreasing flocculation. Increasing 
the ionic strength of SINV solution did not change the removal. While in the case of the 
control studies using water and PBS [6, 7], increasing the ionic strength increased 
removal, likely due to the salting out effect which also affects proteins. Effect of pH on 
the virus interaction for osmolyte flocculation has been shown for PPV. The interaction 
between zwitterionic osmolyte compound and PPV and SINV is favorable near the virus 
pI [6, 7]. When the virus is negatively charged above its pI, there are ionic repulsive 
forces which likely decrease virus aggregation. 
Shear stress studies were carried out which includes incorporation of high stress 
during virus flocculation [6, 7]. Results showed that applying high shear to the 
flocculated samples reduced the removal of viruses as stress is breaking the flocs. 
Keeping the disturbances to the samples to the minimum extent during filtration can help 
to maintain the flocculation and optimize virus yield, demonstrating that pump choice 
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and filtration configuration will be important to the industrial implementation of this 
method. 
Looking at the data for both PPV and SINV, it was determined that mannitol was the 
flocculant that had high removal for both viruses. So, we decided to use mannitol as our 
flocculating osmolyte for further studies to demonstrate recovery and purification. Since 
we were unable to recover the virus from the membrane surface using dead end filtration, 
we also changed the filter configuration to leave virus in solution and relieve the need to 
recover the virus from the membrane filter.  
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Figure 2-3 Screening of osmolytes, salt, PEG, control tris buffer and water for removal of PPV 
and SINV, virus removal was calculated using flocculated virus titers before filtration and after 
filtration. All Experiments performed using 0.2 µm 96-plate filtration, flocculation time allowed 
was 2 hours [6, 7, 116]. Images taken with permission from publisher and author, permission 
attached in the appendix. 
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2.5. Osmolytes 
Osmolytes are naturally occurring compounds found in the cells of many organisms, 
including mammalians and marine animals. As the name osmolyte suggest, they help in 
maintaining osmotic pressure in cells by pulling water towards them, especially marine 
animals who live in high salt environments [117]. This mechanism of osmolytes helps to 
control the cell volume by changing the water content of the cells. Osmolytes are also 
known to stabilize the proteins. There are two types of osmolytes, depending upon their 
action with the proteins, protecting and denaturing. The categories of osmolytes are N-
oxides, amino acids, sugars and polyols, and denaturing, which includes urea and 
guanidine hydrochloride [118]. Protecting osmolytes force protein folding by excluding 
the protein backbone from water molecules as they do not bind directly to the proteins 
while denaturing osmolytes causes the proteins to unfold by binding to the protein 
backbone.  Naturally occurring osmolytes help in stabilizing proteins against denaturing 
stresses by disruption of unfolded state of proteins in the presence of osmolyte [117, 119]  
Although there is no universal theory behind the mechanism of osmolytes 
interaction, work by Street and Bolen has shown that the strength of osmolytes to interact 
with the protein backbone may explain osmolytes ability to stabilize proteins [117]. In 
their study, the ΔG, or Gibbs transfer energy of transfer, was measured for the protein 
backbone being transferred from water to a 1M osmolyte solution. Protecting osmolytes 
have a positive ΔG free energy of transfer, demonstrating that osmolytes interact 
unfavorably with the protein backbone.  This suggests that the osmolytes do not bind to 
the protein backbone. Instead, they are binding to the water around the protein surfaces 
resulting in a depletion of water around the protein backbone. In contrast, denaturing 
osmolytes have a negative ΔG transfer energy, demonstrating a favorable interaction 
between osmolytes and protein backbone.  This suggests that the mechanism of protein 
denaturation by denaturing osmolytes is due to direct binding of the osmolyte to the 
protein backbone. We hypothesize that the ability of protecting osmolytes to control the 
water structure around the proteins can be used as a potential flocculant for the viruses as 
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virus capsids are made of proteins. Our hypothesis is based on the preferential hydration 
mechanism of osmolytes. As due to active hydrophobic surface on virus particles, when 
water is removed around the viruses they tend to aggregate with each other. The addition 
of osmolyte to virus solution will structure water around the viruses, removing water 
around can help the viruses come together to form the bigger flocs due to the 
hydrophobicity of viruses [6, 7, 116]. 
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3. Materials and Methods 
3.1. Materials 
Mannitol (C6H14O6), thiazolyl blue tetrazolium bromide (MTT), sodium dodecyl 
sulphate (SDS) hydrochloric acid (HCl) were purchased from Sigma-Aldrich (St. Louis, 
MO). Reagents for cell culture, minimum essential medium (MEM), phosphate-buffered 
saline (PBS, pH 7.2), 0.25% trypsin/EDTA, and penicillin/streptomycin (pen/strep) and 
gentamicin (gentamicin sulfate) were purchased from Life Technologies (Carlsbad, CA). 
Tryptose phosphate broth (TPB) was purchased from VWR supplier (Radnor, PA). Fetal 
bovine serum (FBS) was purchased from Atlanta Biologicals (Flowery Branch, GA). We 
used NanoPure water with a resistivity of  >18 MΩ.cm (Thermo Scientific, Waltham, 
MA) for all the solution preparation and were sterile filtered using 0.2µm syringe filter 
(Nalgene, Rochester, NY) or with a 0.22 µm bottle top filter (Millipore, Billerica MA). 
For the HPLC study, HPLC grade acetonitrile 99.93% and trifluoroacetic acid (TFA) 
≥99.0% were purchased from Sigma-Aldrich (St. Louis, MO). For TEM work, propylene 
oxide, glutaraldehyde (Grade I, 70% in H2O), sodium cacodylate (BioXtra, ≥98%), lead 
citrate (purum, for electron microscopy) and agarose gel (Type I, low EEO) were 
acquired from Sigma-Aldrich (St. Louis, MO). The embedding kit for preparing samples 
for electron microscopy EMBed-812 embedding kit, osmium tetraoxide 2% aqueous 
solution and uranyl acetate were obtained from Electron Microscopy Sciences (Hatfield, 
PA). 
 
3.2. Cells and Viruses 
3.2.1. Cell culture 
Porcine kidney (PK-13) cells are grown and cultured in (MEM) completed with 10% 
FBS and 1% pen/strep. Baby hamster kidney (BHK) cells are grown and cultured in 
MEM completed with 10% FBS, 5% tryptose phosphate broth (TPB) and 1% gentamicin. 
To maintain the cells, they were washed in PBS, followed by addition of 3 ml of trypsin 
for removing the attached cells from the flask wall. PK-13 cells are more adherent to the 
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flask wall, so after waiting 10 minutes we hit the flask manually to remove cells from 
wall. BHK cells are easily detached from the flask wall in 3-5 minutes. After cells detach 
from the wall, trypsin was neutralized using equal quantity of completed media. Cells 
were separated from trypsin by centrifugation in a Sorvall ST16R Centrifuge (Thermo 
Scientific, Pittsburgh, PA) at 1500rpm for 3 minutes. PK-13 cells were propagated every 
3 days when the confluency reached >80% and a split ratio of 1:5. BHK cells were 
propagated every day with a split ratio of 1:3. All cells were maintained at 37°C, 5% CO2 
and 100% humidity.  
3.2.2. Virus preparation and titration 
PPV virus was propagated in PK-13 cells. PK-13 cells were seeded at a density of 6 
x 105 cells/flask and incubated for about 24 hours, with the goal of 90% cell confluency. 
The media was removed, and the flasks were inoculated with 1 ml of PPV at a 
concentration of 103 MTT50/ml diluted in PBS, 3% FBS and 1% pen/strep. After 1.5 
hours, 9 ml of fresh media was added to the flasks and the infected cells were incubated 
for five days. Flasks were frozen at -20°C, scraped and clarified using centrifugation at 
5000 rpm for 15 minutes at 4°C using Sorvall ST16R Centrifuge (Thermo Scientific, 
Pittsburgh, PA). The clarified virus solution was stored at −80°C. 
SINV was propagated on BHK-21 cells.  Similar procedures were followed for 
preparation of SINV except where noted. After cells were inoculated with SINV, infected 
cells were incubated for two days until the cells lysed. The cells were scraped without 
freezing and clarified. Clarified SINV solution was stored using 10% glycerol and kept in 
-80⁰C until further use for experiments [120]. 
Virus quantification was done using the colorimetric cell viability assay, the MTT 
assay, as described earlier [120]. This assay determines the concentration of infectious 
virus needed to maintain a 50% cell viability. For PPV, PK-13 cells were seeded in a 96-
well plate at a cell density of 8×105 cell per well and for SINV, BHK cells were seeded at 
a cell density of 5×105 cells per well. Plates kept in an incubator for 24 hours and infected 
with samples to be analyzed. Typically, the samples were diluted 5-fold across the 96-
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well plate. After incubation (5 days for PPV, 2 days for SINV) 10 µl/well of 5 mg/ml 
MTT solution (tetrazolium salt (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide) in PBS was added to the plates. After 4 hours the solubilizing agent (0.01 M 
HCl and 10% SDS in water) was added and plates were incubated overnight. The ddition 
of MTT solution forms purple color formazan inside the mitochondria of metabolically 
active cells and the addition of solubilizing agent solubilize this formazan. Upon 
dissolving the formazan crystals, the cell viability was quantified by measuring the 
absorbance of the solution at 550 nm using a Biotek Synergy Mx plate reader (Winooski, 
VT). The virus infectivity was calculated using the MTT50 50% infectious dose value 
which can be determined based on absorbance values of infected cells, as described 
earlier by Heldt et.al [120]. So for this analysis, we grow cells in 96 well plates and infect 
cells in serial dilution manner with the collected virus sample from experiments. After 
infection and incubation MTT solutions mentioned above are added. Based on 50% dose, 
the absorbance values are recorded for average uninfected cell wells. This reflects the 
infectivity in terms of logarithmic factor based on dilution factor. The majority of 
analysis was performed using 5-fold series dilution in 96- well plates, and for high titer 
values 10- fold series dilutions were used. 
 
3.3. Virus Flocculation and Diafiltration 
1M mannitol in NanoPure water was prepared fresh for every experiment to avoid 
dissolution. For flocculation of virus particles with osmolytes, 9720 µl of mannitol and 
405 µl of virus (PPV and Sindbis at 6 log MTT50/ml in PBS, unless stated otherwise) 
were mixed and kept for 2 hours at room temperature with manual rotation every 15 
minutes. This 1M concentration and ratio of osmolyte to the virus was adapted from our 
previous studies in which we used 720 µl osmolyte with 30 µl of the virus [6, 7]. As a 
control, a water and virus mixture were also prepared and kept for 2 hours.  The ratio of 
solutions was kept the same for all experiments with enveloped and non-enveloped virus.  
 Flocculated virus with osmolyte solution was filtered using a batch diafiltration 
method as shown in Figure 3-1. A 10 ml Amicon filtration cell filter (Model 8010), a gift 
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from EMD Millipore, was equipped with different pore size membranes. The membranes 
were Durapore Membrane Filter PVDF 0.2 μm and 0.1 µm and BioMax’s 
polyethersulfone (PES) 500 kDa and 300 kDa MWCO membranes, also gifts from EMD 
Millipore. All membrane size were 25 mm and fits in filter holder of Amicon cell filter 
model 8010. Filtration cells were operated at 10 psi pressure, unless otherwise stated, 
from a compressed nitrogen tank and without stirring as stirring could break the 
flocculated particles. Initially, 10ml of mannitol and virus solution was added to the 
filtration cell, and pressure was applied until 2-3 ml of filtrate was collected, with 2 ml 
being held up in the outlet tubing. This was the first fraction collected for filtrate (Filtrate 
1 or F1). A 300 µl sample was removed from the retentate and labeled retentate 1 (R1). 
After collection of the first fraction, 5 ml of 1M mannitol was added to make a total of 10 
ml solution in the filter unit.  The pressure was applied to the filtration cell unit and the 
second fraction was collected. Similarly, for the third fraction, 5 ml of mannitol was 
added and filtrate (F3) and retentate (R3) were collected immediately. The diafiltration 
method is illustrated in Figure 3-1. As a control, the same procedure was applied using 
water instead of mannitol and all samples were analyzed by titration using an MTT assay 
mentioned earlier in section 3.2. 
As we are adding more diavolumes to the diafiltration for collecting second and third 
fractions, the addition of more osmolyte solution may be causing breaking of flocs, to 
solve this problem we decided to perform flocculation time studies in between the 
fractions. In flocculation time studies, after addition of osmolyte, we allowed settling the 
virus and osmolyte solution more time prior to filtration. All samples collected were 
analyzed using the MTT assay. 
 
 32 
 
Figure 3-1 Batch diafiltration setup for recovery of infectious virus particles using filtration cell 
with manual addition of virus and mannitol, samples collected in three fractions with 5ml 
addition of mannitol at 2nd and 3rd fraction 
  
 We also explored different concentrations of infectious virus particles as a starting 
material for flocculation. A variety of starting concentrations were analyzed using the 
same parameters as stated earlier with diafiltration. Mannitol solution for all samples was 
prepared in water at 1M concentration unless otherwise stated. For the high concentration 
titer solutions (log 11 MTT50/ml for PPV and log 10 MTT50/ml for SINV), 1M mannitol 
was prepared in virus solution instead of water to avoid dilution of virus concentration 
taking measured quantity of mannitol powder dissolved into virus solution.  
All the results obtained through MTT assay gave the titer values for each collected 
samples. The MTT50/ml values were converted into mass per MTT based on the volume 
of samples. The step yield of infectious virus particles was calculated at each fraction of 
retentate with respect to input at each fraction as shown following equations i. 
 
𝑌𝑖 = (
𝑀𝑎𝑠𝑠 𝑝𝑒𝑟 𝑀𝑇𝑇 𝑓𝑜𝑟 𝑟𝑒𝑡𝑒𝑛𝑡𝑎𝑡𝑒 𝑖
𝑀𝑎𝑠𝑠 𝑝𝑒𝑟 𝑀𝑇𝑇 𝑓𝑜𝑟 𝑖𝑛𝑝𝑢𝑡 𝑖𝑛 𝑖𝑡ℎ 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛
   ) × 100 
(i) 
 
Where Yi represents step yield in the fractions, where i starting from 1. Step yield 
calculations were performed considering input at each fraction as we are removing some 
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quaintly from retentate for the analysis thus reducing the number of particles in each 
input. All percent recovery values for each experiment were averaged over repeated 
experiment to get more accurate data. After calculation of step yield at each fraction, 
overall yield was calculated based on step yield for 2nd and 3rd fraction as described 
earlier in equation (i), where for 2nd fraction it will be i+1, and for 3rd fraction i+2. 
Recovery for first remains the same for unit yield calculations, and overall yield 
calculations were performed using equation (ii). 
 𝑂𝑣𝑒𝑟𝑎𝑙𝑙 𝑌𝑖+1 = 𝑌𝑖+1 × 𝑌𝑖 (ii) 
 
3.4. HPLC C-18 Chromatography 
The samples collected from diafiltration using the 0.1 µm filters for PPV were 
analyzed for purification using reverse phase chromatography (RP-HPLC). A Waters 
XBridge BEH C18 Column 4.6 mm × 150 mm was used for samples analysis on a 
Waters® e2695 HPLC equipped with a Waters 2998 Photodiode array detector UV/Vis 
spectrophotometer detector. A sample volume of 10 µl was injected onto the column, and 
all the samples were run at the same conditions. The mobile phase used for started at 
100% buffer A, comprised of 0.1% TFA in water, and an increasing buffer B, comprised 
of 0.1% TFA in acetonitrile. The flow rate for all samples was maintained at 0.500 
mL/min, a sample temperature of 15°C and a column temperature of 25°C. The column 
was washed in between samples using 100% acetonitrile. The area under the peak was 
analyzed using Empower software which uses the numerical integration method using 
trapezoidal rule equation (iii). 
𝐴𝑟𝑒𝑎 𝑢𝑛𝑑𝑒𝑟 𝑡ℎ𝑒 𝑐𝑢𝑟𝑣𝑒 = (𝑡2 − 𝑡1) [
𝑓(𝑡1)+𝑓(𝑡2)
2
]    (iii) 
 Where t1 and t2 are the time range for chosen peaks with respect to UV absorbance 
value at that times. Using the area under the curve, we further calculated percent removal 
of peak area in different peaks using equations (iv) and (v) where ABF represents area 
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under the curve of before filtration sample, AF1 for filtrate F1, and AR1 for retentate R1 
sample. 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑟𝑒𝑚𝑜𝑣𝑎𝑙 𝑖𝑛 𝐹𝑖𝑙𝑡𝑟𝑎𝑡𝑒 𝐹1 = (
𝐴𝐵𝐹−𝐴𝐹1
𝐴𝐵𝐹
) ∗ 100    (iv) 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑟𝑒𝑚𝑜𝑣𝑎𝑙 𝑖𝑛 𝑅𝑒𝑡𝑒𝑛𝑡𝑎𝑡𝑒 𝑅1 = (
𝐴𝐵𝐹−𝐴𝑅1
𝐴𝐵𝐹
) ∗ 100   (v) 
 
3.5. DNA Quantification 
DNA quantification was done using the Quant-iT PicoGreen (Invitrogen, Eugene, 
OR) dsDNA reagent. All the samples collected from diafiltration were analyzed for 
dsDNA contents. For PPV and SINV infectious particles recovery, diafiltration was done 
using 0.1 µm pore size filter, and concentration of PPV and SINV used at log 8 
MTT50/ml. At lower concentration of log 6 MTT50/ml for PPV and SINV, we were 
unable to detect DNA content as it was below detectable threshold levels. For preparing 
all PicoGreen reagent 10mM Tris-HCL1 1mM EDTA buffer (TE Buffer) was used at pH 
7.5. A standard curve was obtained using Lambda DNA standard at 2 different range of 
standard 1 ng/mL to 1 μg/mL and 25 pg/mL to 25 ng/mL so as to detect even low 
concentration of DNA contents. PicoGreen reagent and DNA standard are diluted using 
TE buffer. All reagents prepared in a plastic container rather than glass as reagent may 
absorb to a glass surface and also protected from light using aluminum foil as reagents 
are light sensitive. The lambda DNA standard, given at 100 μg/mL concentration in the 
kit, dilute it to 50-fold in TE buffer to make the 2 μg/mL as base solution. This 2 μg/mL 
is diluted in series and used for standard curves. Then added aqueous working solution of 
Quant-iT PicoGreen reagent to each well of 96-well plate along with standard DNA 
samples and unknown samples from diafiltration. After mixing well and incubating for 2-
5 minutes at room temperature protected from light, 96-well plates were read at 
fluorescein wavelengths (excitation ~480 nm, emission ~520 nm) with a fluorescence 
microplate reader Synergy Mx plate reader. Calculations for our samples DNA 
quantification was performed using slope equation of standard curve for both standard 
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range and low concentration range also. Removal of DNA content per step in retentate 
samples was calculated using equation (vi). 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑟𝑒𝑚𝑜𝑣𝑎𝑙 𝑜𝑓 𝐷𝑁𝐴 = (1 − (
𝐷𝑁𝐴 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑖𝑛 𝑟𝑒𝑡𝑒𝑛𝑡𝑎𝑡𝑒
𝐷𝑁𝐴 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑖𝑛 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑖𝑛𝑝𝑢𝑡
 )) × 100   
          (vi) 
DNA removal at each fraction was calculated using equation (vi) and input at each 
fraction was taken into consideration the amount of sample removed for analysis to get 
more accurate results over each fraction. 
 
3.6. Transmission Electron Microscopy 
For studying flocculation of PPV with mannitol, TEM imaging of flocculated and 
non-flocculated samples were taken. Samples prepared as a mixture of 1M mannitol with 
PPV (720 µl mannitol and 30 µl PPV at log 6 MTT50/ml and similarly with water with 
PPV (720 µl water and 30 µl PPV at log 6 MTT50/ml) and allowed for flocculation for 2 
hours. Flocculated virus samples were then inactivated before imaging for safety purpose 
using 0.5% glutaraldehyde for 1 hour [121]. Samples were mounted directly on copper 
grids (EMS200-Cu, Electron Microscopy Sciences) using 10 µl sample with micro-
pipette and air dried overnight. Grids were washed in nanopure water and then stained in 
droplets of 2% uranyl acetate on the parafilm wax paper for 2 minutes. Grids were 
washed again after staining with pure water to prevent contamination. TEM images were 
captured on a JEOL JEM-2010 (Peabody, MA) and imaging was done at 80 kV and 
30000x magnification and 40000x magnification. 
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4. Results and Discussion 
To develop a platform approach, we have selected non-enveloped PPV and 
enveloped SINV as model viruses to explore the potential of flocculation as a universal 
platform virus purification process. Our previous work has demonstrated that a range of 
osmolytes such as alanine, glycine, trehalose, mannitol successfully flocculate viruses 
and not model proteins. This is likely due to preferential hydration that causing virus 
aggregation. From the screened osmolytes, 3 M glycine was able to remove 96% PPV 
particles, and 1 M mannitol showed >80% PPV removal [6]. We also showed mannitol 
flocculation for enveloped SINV particles was able to achieve 96% removal at a mannitol 
concentration of 0.3 M [7]. From this work, in an effort to develop a novel virus recovery 
and purification process we decided to pursue flocculation with mannitol as it worked for 
both model enveloped and non-enveloped virus systems. We are using mannitol at 
optimal 1M concentration to work with both PPV and SINV virus purification and 
recovery. 
4.1. Recovery of Non-Enveloped Porcine Parvovirus (PPV) 
   
4.1.1. Overall recovery of PPV using different filter pore size 
The first parameter studied was with different filter pore size. PPV is a small 
mammalian virus with a diameter of 18-24nm [13, 14]. The screening work demonstrated 
that PPV could be withheld with a 0.2 μm filter. However, since we wanted high 
recoveries for such a small virus, we decided to start with the largest pore size of 0.1 μm. 
The results are shown in Figure 4-1-A.  The largest pore size was able to obtain a 
recovery of 58% and the smallest pore size, a 300 kDa MWCO membrane, was able to 
recover 85% of the infectious particles, demonstrating that as the pore size was reduced, 
the recovery increased. Both pore sizes showed a significant difference from the water 
negative control as smaller virus particles of PPV in water were able to pass through the 
membrane pores, but mannitol caused flocculation to allow the virus to be withheld by 
the filter. For the 500 kDa MWCO membrane, the negative control recovery was not 
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significantly different from the mannitol recovery. This could be due to self-aggregation 
of viruses in that batch during virus production based on the contaminant concentration in 
specific batches. High contaminants in virus stock may cause HCP aggregates and pore 
plugging in control studies. We also measured the amount of virus in the filtrate, and the 
mass balanced closed. Therefore, there was no indication that the virus was absorbing to 
the membranes or the filter housing.  
 
Figure 4-1 Recovery of porcine parvovirus using different pore size filters. A: Comparison of the 
recovery of PPV using 1M mannitol and the negative control water. B: Step yield of retentate 
samples for flocculation with 1M mannitol after each batch diafiltration fraction. Details are 
shown in Figure 3-1. Error bars are the standard deviation of three separate trials *p<0.05 
 To explore the ability of this system to recovery infectious in diafiltration mode, 
we did additional batch fractions by adding pure mannitol to replace the filtrate volume. 
This is shown in Figure 4-1-B. Each fraction remained at a consistent recovery except 
for the smallest pore size, where the 2nd and 3rd fraction dropped due to disturbances in 
the filtration unit while adding more mannitol. As we are adding more mannitol to 
system, we are filtering immediately, this allows very less time for osmolyte flocculation 
for interaction.  As the aggregates are temporary manual disturbances in system breaks 
aggregates and smaller virus particles are passing through the membrane. 
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4.1.2. Flocculation time effect 
To increase the recovery of the 2nd and 3rd fractions, we increased the incubation 
time. The flocculation time of the first fraction was set at 2 hours due to the 2 hours 
quiescent time that was used in the original screening work [6, 7], but the subsequent 
fractions were only given 5 minutes from the addition of mannitol until the filtration. Our 
previous work also demonstrated that the flocs are sensitive to shear stress [6, 7]. 
Therefore, it was hypothesized that the filtration immediately after mannitol addition 
could have broken the flocs from the shear stress of mixing. We increased the filtration 
time as shown in Table 4-1. The times were randomly chosen to minimize waiting time 
and to optimize experimental duration as no previous studies had been performed on the 
time effect of osmolyte flocculation. The results of increasing the time can be found in 
Figure 4-2. There was not a significant difference between the recovery of PPV at the 0.1 
µm filter size. However, the averages vary due to the large error that is found in the MTT 
assay used to measure these values. 
Table 4-1 Flocculation time effect between fractions of diafiltration for PPV 
Fraction Original diafiltration timea Increased diafiltration 
time 
1st fraction 2 Hours 2 Hours 
2nd fraction Immediate fraction collection after 
addition of mannitol 
45 minutes flocculation time  
3rd fraction Immediate fraction collection after 
addition of mannitol 
30 minutes flocculation time   
aDiafiltration time in Figure 4-1. 
 
As a control study, the PPV solution was flocculated with water instead of mannitol 
(data not shown). Control study results show that there is no difference in the recovery 
with normal flocculation and timed flocculation study and the overall recovery is 16% in 
the first fraction with water as flocculation agent. In conclusion, we did not observe a 
significant difference in PPV recovery with increased hold time between fractions. We 
saw in the figure 4-1 that addition of more mannitol gives very little improved recovery 
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(no statistical difference) and allowing time between fraction shows less difference in 
significant flocculation effect.  In future allowing higher time for flocculation in between 
fraction can be tested to see does it help in aggregation. 
 
 
Figure 4-2 Flocculation time effect in between the fractions during diafiltration using a 0.1 µm 
pore size membrane for PPV, Comparative study of step yield of PPV with original diafiltration 
time (green columns) and increased flocculation time (red columns) using 1M mannitol 
flocculation. Error bars are the standard deviation of three separate trials. 
 
4.1.3. Recovery of PPV with different starting concentration 
To study the effect of the starting material concentration on flocculation, we 
explored different initial PPV concentrations, and the results can be seen in Figure 4-3. 
All the diafiltration experiments were carried out at a back pressure of 10 psi, however, 
for the log 11 MTT50/ml, the pressure required for a system for flow-through was 30 psi. 
This indicates that there was membrane fouling at the higher PPV concentrations as flux 
is decreased. Results from this study show that using a starting material concentration of 
log 9 MTT50/ml increases the recovery of PPV in the retentate as compared to previous 
experiments with log 6 MTT50/ml starting concentration.  
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We also explored the recovery of different diafiltration fractions, shown in Figure 4-
3-B. Even though no wait time was given for the flocculation, the recoveries remained 
similar to the first fraction. 
 
Figure 4-3 Recovery of porcine parvovirus with different starting PPV concentrations as log 6, 
log 9 and log 11 MTT50/ml with diafiltration experiments, the filter used for all experiments is 0.1 
µm. A: Comparative percent recovery with mannitol and control water for 1st fractions. B: The 
step yield using 1M mannitol and PPV with different concentration for all collected fractions 
during diafiltration. Statistical difference is calculated using Avona factor between mannitol and 
water 1st fractions, *p<0.05. Error bars are the standard deviation of three separate trials. 
 
4.1.4. Purification of PPV 
The protein content of samples after diafiltration was analyzed using HPLC reverse 
phase chromatography on the C18 column. As we perform the diafiltration, the impurities 
from serum proteins present in the cell culture media are hypothesized not to be affected 
by mannitol flocculation. Thus after filtration, the impurities will pass through the filter 
and the retentate should contain the virus and a lower concentration of serum proteins. 
Since the total serum protein content was low to begin with, we used reverse phase 
chromatography to measure the protein content. In Figure 4-4 we can see the 
chromatographs for PPV flocculated with mannitol before filtration, after filtration, and 
the PPV retentate. We performed this study in duplicates for each sample to make sure to 
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minimize any error in sample eluting. From the chromatographs, we can see that before 
filtration and filtrate are showing 2 major peaks while retentate graph has no major peaks. 
The analysis shows that with diafiltration, we are able to purify the retentate from the 
bovine serum albumin which is coming from the fetal calf serum in the completed media. 
 
 
Figure 4-4 Purification of PPV using diafiltration. Reverse phase chromatography using C-18 
column of the diafiltration samples collected with 0.1 µm pore size membrane before 
filtration(purple), after filtration (dashed orange), and retentate (dotted green) with buffer A as 
0.1% TFA in water and eluting buffer B as 0.1% TFA in acetonitrile (dotted blue line). 
 
Further, we also determined the area under the curves of the peaks in the 
chromatograms to calculate the percent removal of impurities using equation 3.8. The 
area under the curve was taken from area integration calculation from the Empower 
software that controls the HPLC. With our calculations, the percent removal of impurities 
in the retentate PPV sample was found out to be 85% as compared to the before filtration 
sample. This is an acceptable result for a single diafiltration pass. We are able to get good 
recovery and high purification as recovery above 30% is acceptable standard in the 
industries [101]. More purification may be possible with the additional diafiltration 
fractions. With the successful recovery of infectious PPV particles and purification from 
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HCP, this is a good ground for future work to setup a prominent downstream processing 
using osmolyte flocculation and microfiltration. 
4.1.5. DNA quantification for PPV 
DNA quantification was performed on all the diafiltration collected samples before 
filtration and after filtration samples were analyzed to see whether flocculation with 
osmolytes helps to remove the host cell DNA contents from virus particles. Results show 
in Figure 4-5 that the negative water control is able to remove more DNA than mannitol 
flocculation. Therefore, the osmolytes likely flocculate the DNA. DNA removal for PPV 
was about 45% in the first fraction and less than 7% DNA removal in next fractions due 
to the addition of mannitol flocculated DNA remaining from the previous step. While in 
the case of water, as there is no flocculation mechanism occurring it was not affecting the 
DNA content and it was showing DNA content removal >60% in 1st fraction and about 
40% in each next fractions. This was due to flushing out the DNA from the retentate. 
 
Figure 4-5 DNA quantification for PPV. Percent removal of DNA in retentate samples for PPV 
by mannitol flocculation using Picogreen DNA quantification. All samples collected using 0.1 
µm filter pore size membrane and titer log 9 starting material for diafiltration. Error bars are the 
standard deviation of two separate trials 
 
 
 
 43 
4.1.6. Overall PPV Recovery 
The overall summary for the purification and recovery of PPV is shown in Table 
4-2. This data shows that in the retentate samples, we were able to retain high PPV titers, 
however, we did not concentrate the virus particles. Concentration would have been 
expected since the volume of each retentate samples is reduced by half. Recovery 
increases with each fraction for the water control because the starting titer of each unit 
drops. The overall recovery includes all fractions earlier. It can be seen that the overall 
PPV recovery after 3 fractions with the 0.1 um filter is not statistically different from the 
water control, but the titer is a little higher. For the smaller pore size filters, it is even 
more pronounced. More work is needed to improve the recovery of the virus in later 
fractions. As shown previously, the DNA removal with mannitol flocculation found was 
low because mannitol is likely flocculating DNA during diafiltration. As DNA are 
charged particles, reasonable explanation for DNA being aggregated in presence of 
mannitol can be the reduction of electrostatic forces due to mannitol. This leads to DNA 
being aggregated and retained above membranes in retentate. Protein recovery was 
calculated from reverse phase chromatography and shows an 85% protein removal which 
comes from the cell culture media used in the virus preparation. 
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Table 4-2 Overall recovery and purification of PPV,. Comparison of concentrations before and 
after diafiltration, step yield, overall recovery with different filter pore size using diafiltration for 
PPV recovery along with DNA removal and protein removal for mannitol  
PPV  Flocculation with mannitol 
Filter 
pore 
size 
DNA 
removala 
(%) 
Protein 
removalb 
(%) 
Starting 
concentration 
(MTT50/ml) 
Final retentate 
concentration 
(MTT50/ml) by 
fraction 
Step yieldc 
(%) by 
fractions 
Overall 
recoveryd 
(%) by 
fraction 
0.1 µm 45 85 6.63 ± 0.1 1st 6.35 ± 0.2 58 ± 19   58 ± 19 
2nd 5.75 ± 0.3 37 ± 20   21 ± 15 
3rd 5.47 ± 0.4 52 ± 17 10 ± 9 
500 
kDa 
- - 6.93 ± 0.5 1st 6.70 ± 0.5 60 ± 14   60 ± 14 
2nd 5.29 ± 0.4 43 ± 17 25 ± 8 
3rd 5.94 ± 0.6 53 ± 22 11 ± 1 
300 
kDa 
- - 6.47 ± 0.2 1st 6.55 ± 0.2 85 ± 11   85 ± 11 
2nd 6.06 ± 0.1 57 ± 33   53 ± 31 
3rd 5.86 ± 0.1 58 ± 16   36 ± 22 
 
  Negative control flocculation with water 
0.1 µm 63 0  6.60 ± 0.2 1st 5.84 ± 0.2 17 ± 2 17 ± 2 
2nd 5.43 ± 0.3   44 ± 22   7 ± 2 
3rd 5.29 ± 0.3   77 ± 27   7 ± 4 
500 
kDa 
- - 7.04 ± 0.7 1st 6.68 ± 0.8 43 ± 9 43 ± 9 
2nd 6.01 ± 0.7   23 ± 14   9 ± 3 
3rd 5.09 ± 0.5 29 ± 3   2 ± 1 
300 
kDa 
- - 6.61 ± 0.4 1st 5.96 ± 0.3 20 ± 9 20 ± 9 
2nd 5.64 ± 0.3   55 ± 31   12 ± 11 
3rd 5.44 ± 0.3   81 ± 24   8 ± 3 
Error bar are standard deviation from three trials. 
a: Based on Quant-iT PicoGreen dsDNA quantification method 
b: Based on area under the curve calculations from reverse phase chromatography (RPC) 
c: Based on infectious particles titer calculations using MTT50 assay for step yield calculations 
from equation 3.1-3.3 
d: Based on infectious particles titer calculations using MTT50 assay overall recovery calculation 
from equation 3.1, 3.4 & 3.5. 
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4.2. Recovery of Enveloped Sindbis Virus 
 
4.2.1. Recovery of SINV using different filter pore size 
 
For the recovery of enveloped SINV, experiments were carried out using 1M 
mannitol flocculation followed by diafiltration. We started the diafiltration study with a 
0.2 µm pore size filter and then studied smaller pore size filters. As the size of SINV is 
about 50nm [14, 44], we want to accomplish high recovery using as large pore size filter 
as possible. While in the case of PPV, we started with 0.1 µm pore size filter because of 
the small size of PPV. Figure 4-6-A showing percent recovery for SINV in the first 
fractions of retentate using different pore size membrane filters with mannitol 
flocculation and water as control. Recovery of infectious SINV particles using 0.2 µm 
filter shows 65% with mannitol. Using 0.1 µm membrane for the same experiments 
shows increased recovery of 77%. Further using smaller membrane of 500 kDa achieved 
96% recovery of infectious virus particles in the retentate. A control study for all pore 
size shows no significant recovery. When a 300kDa membrane was used, SINV was 
withheld with the control water. Comparative study of different pore size shows an 
increase in the recovery as we use smaller pore size filter, while control sample does not 
show increased recovery. This demonstrates that recovery of particles is based on the 
bigger flocs of viruses formed due to mannitol flocculation.  
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Figure 4-6 Recovery of SINV using different pore size, using 0.2 μm, 0.1 μm, 500 kDa pore size 
filter with diafiltration method, A: Percent recovery in 1st fraction of diafiltration retentate 
samples for flocculation with 1M mannitol and control water for different membrane pore size. B: 
The step yield in all fractions using mannitol flocculation for each filter membrane pore size. 
Error bars are the standard deviation of three separate trials *p<0.05 
 Looking further into each fractions of diafiltration, Figure 4-6-B shows results for 
all fractions along with different pore size membranes. Studies with 0.2 µm and 0.1 µm 
show consistent recovery in all fractions with mannitol flocculation method. Smaller pore 
size filter 500 kDa was used for diafiltration to achieve a high recovery of infectious 
virus particles. With 500 kDa pore size filter, we performed diafiltration, and the 
recovery of SINV particles was about 96% in the first fraction using 1M mannitol 
flocculation. This is the highest recovery of SINV achieved using 3 different pore size 
filters as 0.2 μm, 0.1 μm, and 500 kDa filters. After addition of more diavolumes 1M 
mannitol to the retentate from the first fraction and performing filtration, in the second 
fraction of retentate it is showing 67% recovery and 69% recovery in the 3rd fraction of 
retentate as shown in Figure 4-6-B. As a control for study with all the three different 
pore size filter, water is showing low recovery of infectious SINV, which suggesting that 
water is not affecting the size or flocculation of virus particles at all. Comparing results 
from Figure 4.6-A and 4.6-B, we can see that we are able to get high virus recovery with 
mannitol flocculation as compared to water flocculation. 
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4.2.2. Flocculation Time Effect 
Similar studies as mentioned in previous section 4.1.2 for the non-enveloped virus 
for flocculation time studies was carried out with enveloped SINV. Keeping all the 
parameters for the study similar except the flocculation time in between the fraction. We 
performed flocculation time studies using 0.2 µm filter pore size and compared results 
with 0.2 µm diafiltration without additional waiting time during fractions. Time allowed 
in between the 1st and 2nd fraction was 45 minutes and for 2nd and 3rd fraction time 
allowed 30 minutes as shown in Table 4-3. 
The ratio of the virus with mannitol or water and the initial flocculation time were 
kept the same for both studies. The recovery of infectious SINV was 66 % in the 1st 
fraction of retentate which is same as we have seen in normal flocculation study as shown 
in Figure 4-7. After allowing more flocculation time before filtering the 2nd fraction, a 
significant increase in recovery was observed. Improved recovery can also be seen in 3rd 
fraction after allowing more flocculation time, however, there was no statistical 
difference shown. While looking at the water control, it showed no effect of flocculation 
time between fractions there was no significant rise when the flocculation before the 2nd 
and 3rd fractions was increased (data not shown).  
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Figure 4-7 Flocculation Time Effect in between fractions during diafiltration using 0.1 µm 
MWCO for SINV with 1M mannitol. Comparative study of the step yield of SINV with normal 
diafiltration (green) and allowing flocculation time in between the fractions (red), Error bars are 
the standard deviation of three separate trials *p<0.05 
 
4.2.3. Recovery of SINV with different starting concentration 
Different starting material concentration log 6, log 9, log 10 MTT50/ml of SINV was 
added for the flocculation experiments to study the effect of concentration for recovery of 
virus particles. All experiments were performed using a 0.1 µm membrane filter to have 
the same comparison across all concentration range and with PPV.  Using a higher 
concentration of SINV for log 10 MTT50/ml shows there is significant membrane fouling 
with low throughput at the membranes and pressure required for the system is about 30 
psi, while for the lower concentration of log 6 and log 9 MTT50/ml and SINV pressure 
required for the system is 10 psi.  
Figure 4-8-A shows the percent recovery of SINV using different initial 
concentration for mannitol and the negative water control. First fractions with mannitol 
using log 9 MTT50/ml SINV concentration showed 79%. Increasing concentration to log 
10 MTT50/ml we are able to get 90% recovery of SINV. No significant high recovery was 
observed with the negative control, except for the log 11 MTT50/ml. Note that the 
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membrane fouling that occurred at high concentration of virus, causing partial recovery 
with the water control.  
 
Figure 4-8 Recovery of SINV showing different starting concentration as log 6, log 9 and log 10 
MTT50/ml with diafiltration experiments, A: Overall yield of SINV in presence of mannitol and 
control, B: Step yield for SINV showing all 3 fractions recovery in presence of mannitol only. 
Membrane filter used for all experiments is 0.1 µm, Error bars are the standard deviation of three 
separate trials *p<0.05 
Further details into each fraction of mannitol flocculation samples are shown in 
Figure 4-8-B. Results with log 6 MTT50/ml SINV concentration were explained 
previously in section 4.2.1. Using log 9 MTT50/ml of SINV shows 79% recovery in first 
fraction which is about the same for log 6 MTT50/ml concentration for SINV. In the 2
nd 
and 3rd fraction recovery is 44% and 49% respectively due to braking of aggregates in 
manual addition. Increasing the initial concentration of SINV to log 10 MTT50/ml and 
1M mannitol without diluting in water, higher recovery was recorded. In the 1st fraction 
recovery of 90% achieved followed by consistent recovery in each subsequent fractions.  
4.2.4. Purification of SINV 
For the diafiltration of SINV, we collected fractions of filtrate, retentate and 
compared with before filtration samples for the purification validation using reverse 
phase chromatography (RPC) using C18 column. As we hypothesis, we expected HCP 
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will pass through the membrane after flocculation and microfiltration and purified SINV 
should be retained. Several repeated HPLC analysis for the SINV diafiltration 
experiment, it was not showing high purification. The total protein concentration in the 
SINV preparations was very low because the virus was stored in glycerol during freezing. 
We had to remove the glycerol with dialysis prior to HPLC, but it also removed many of 
the contaminating proteins. The graphs in Figure 4-9 showing the chromatographs of 
before filtration sample, filtrate sample and retentate. The before filtration sample shows 
contaminant BSA peak at time 20-21 minutes (second peak on the continuous line curve), 
filtrate is showing reduced contaminant while retentate has the contaminant BSA peak 
(green dotted line curve). Area under the curve calculations shows that we were able to 
remove about 37% of contaminant in the retentate sample, but starting concentration of 
protein content was very low. To overcome low detectable values for HCP, we prepared 
samples with added impurities (conditioned media as representative for HCP) and still 
analysis was unable to get proper purification data.  While in case of PPV purification, 
we demonstrated 80% contaminant protein removal using same diafiltration experiment 
with 1M mannitol.   
 
Figure 4-9 Purification of SINV analysis using Reverse phase chromatograph using C-18 column 
of the diafiltration samples before filtration(purple), after filtration (dashed orange), and retentate 
(dotted green) with buffer A as 0.1% TFA in water and eluting buffer B as 0.1% TFA in 
acetonitrile (dotted blue line) 
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4.2.5. DNA Quantification 
 In case of SINV diafiltration experiments, all collected fractions were analyzed 
for DNA content for DNA removal. Samples collected from mannitol flocculation 
demonstrate partial flocculation of DNA in first fraction as removal is about 50%, as 
shown in Figure 4-10 but further addition of mannitol decreased removal of DNA. 
Samples with water as control showing higher removal than with mannitol. So addition of 
water is not affecting DNA removal, while addition of mannitol has opposing effect on 
DNA removal. Mannitol flocculation was flocculating DNA also so we were unable to 
get high removal of DNA in retentate. As DNA are charged particles, possible 
explanation for DNA being aggregated in presence of mannitol can be the reduction of 
electrostatic forces due to mannitol. To solve this problem and achieve better DNA 
removal during diafiltration we would like to further study using benzonase endonuclease 
treatment as several literatures have shown DNA removal using benzonase endonuclease 
[86, 122]. We can use this endonuclease for removing DNA content from our virus 
samples prior to flocculation and filtration which is effective method for removing DNA 
as a future work. 
 
Figure 4-10 DNA quantification for SINV . Percent removal of DNA in retentate samples for 
SINV by mannitol flocculation using Picogreen DNA quantification. Diafiltration performed 
using 0.1 μm membrane with log 9 SINV concentration. Error bars are the standard deviation of 
two separate trials 
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4.2.6. Overall Summary for enveloped SINV 
Looking at the overall recovery and purification for SINV, Table 4-3 shows the 
comparative data for DNA removal, protein removal, concentrations and recovery by 
fractions. DNA quantification and protein removal study by reverse phase 
chromatography was performed on samples collected by 0.1 µm membrane based 
diafiltration. Concentrations in terms of MTT50/ml are showing the infectious virus titers 
in each fractions of retentate samples. For samples from diafiltration using 0.1 µm, 500 
kDa and 300 kDa membrane, with starting concentration of SINV, we can see in retentate 
we are able to get high titer values close to starting concentration in first fraction and then 
decreasing titer in next fractions. While our negative control shows drop in the 
concentration of retentate after diafiltration.  
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Table 4-3 Overall recovery and purification of SINV, Comparison of concentrations before and 
after diafiltration, step yield, overall recovery with different filter pore size using diafiltration for 
SINV recovery along with DNA removal and protein removal for mannitol 
SINV Flocculation with mannitol  
Filter 
pore 
size 
DNA 
removala 
(%) 
Protein 
removalb 
(%) 
Starting 
concentration 
(MTT50/ml) 
Final retentate 
concentration 
(MTT50/ml) by 
fraction 
Step 
yieldc 
(%) by 
fractions 
Overall 
recoveryd 
(%) by 
fraction 
0.2 µm 49 37 6.43 ± 0.2 1st 6.33 ± 0.5 65 ± 24 65 ± 24 
2nd 5.95 ± 0.5 52 ± 24 45 ± 25 
3rd 5.77 ± 0.5 58 ± 30 35 ± 20 
0.1 µm - - 7.03 ± 0.8 1st 7.10 ± 0.5 77 ± 31 77 ± 31 
2nd 6.96 ± 01 79 ± 20 62 ± 24 
3rd 6.64 ± 0.6 72 ± 36 45 ± 18 
500 
kDa 
- - 6.07 ± 0.7 1st 6.10 ± 0.7 96 ± 5 96 ± 5 
2nd 5.89 ± 0.7 67 ± 7 71 ± 8 
3rd 5.39 ± 0.7 69 ± 3 46 ± 2 
 
 Negative control flocculation with water 
0.2 µm 62 35  6.69 ± 0.2 1st 6.03 ± 0.5 20 ± 13 20 ± 13 
2nd 6.20 ± 0.5 86 ± 22 32 ± 24 
3rd 5.77 ± 0.8 48 ± 27 20 ± 18 
0.1 µm - - 7.55 ± 1 1st 6.63 ± 1 21 ± 31 21 ± 21 
2nd 6.50 ± 1 65 ± 26 22 ± 18 
3rd 5.26 ± 1 76 ± 39 21 ± 24 
500 
kDa 
- - 6.95 ± 1 1st 6.35 ± 1 29 ± 16 29 ± 16 
2nd 5.66 ± 0.7 36 ± 28 11 ± 7 
3rd 5.60 ± 0.9 74 ± 23 7 ± 4 
Error bar are standard deviation from three trials. 
a: Based on Quant-iT PicoGreen dsDNA quantification method 
b: Based on area under the curve calculations from reverse phase chromatography (RPC) 
c: Based on infectious particles titer calculations using MTT50 assay for step yield calculations 
from equation 3.1-3.3 
d: Based on infectious particles titer calculations using MTT50 assay overall yield calculation 
from equation 3.1, 3.4 & 3.5. 
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4.3. Transmission Electron Microscopy  
 
To support the flocculation hypothesis along with all the results shown earlier, we 
performed imaging of the flocculated virus particles in osmolyte solution. In Figure 4-11 
it is showing images for flocculated PPV in mannitol and in water as a control. Figure 4-
11 A and B are showing that PPV particles in mannitol at two different resolutions. 
Aggregates are easily found. The aggregate size around 100 nm is also supported by the 
filtration results that below a 0.1 um filter, there is a rise in virus found in the retentate. In 
comparison, images of PPV in water (shown in Figure 4-11 C and D) showed separated 
and individual particles. This further supports the theory that mannitol is causing virus 
flocculation. 
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Figure 4-11 Transmission electron microscope images for PPV sample in mannitol and water. 
Figure A (100 nm) & B (500 nm) shows PPV with mannitol, Figure C (100 nm) & D (500 nm) 
showing PPV with water 
 
4.4. Discussion 
To prove our hypothesis that mannitol flocculation works for all types of viruses and 
can be applied as a novel platform approach with minimal changes, we studied the non-
enveloped PPV and enveloped virus, SINV. For both viruses, osmolyte mannitol was 
able to flocculation based on our results of virus retentions using large pore sixe filters. 
Addition of mannitol, removes the bound water around the viruses due to preferential 
hydration of osmolyte. Section 4.1, shows recovery and purification data for PPV. We 
got 58% recovery using 0.1 µm filter for the PPV and highest recovery of 85% was 
achieved using 300 kDa filter. In Section 4.2, we have shown all the results for recovery 
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of SINV using different pore size filter such as 0.2 µm, 0.1 µm and 500 kDa filters. 
Using 0.2 µm pore size filter we were able to obtain a 65% recovery in the first fraction 
and 79% recovery using a 0.1 μm pore size filter. Highest recovery was achieved using a 
500 kDa pore size filter which was 96%. As we are using different pore size filter, 
recovery of infectious SINV particles was increasing with decreasing filter pore size. 
Considering the size of SINV, which is about 50 nm, we are able to recover SINV 
particles even with large pore size filter as 0.2 μm. As a control study and to show 
mannitol is responsible for forming the flocs of virus. We also performed control studies 
with water. As seen in our previous results from section 4.1 and 4.2, it is showing that the 
percent recovery of virus particles is low or virus particles are passing though the filter 
while performed with water.  
This recovery using microfiltration is significantly promising as compared to the size 
of virus. In literature review, we have seen studies for recovery of viruses using small 
MCWO membranes such as 30 kDa, 50 kDa and 100 kDa for parvovirus MVM (22-26 
nm size) [98] and  Aedes aegypti densonucleosisvirus (20-30 nm) [91, 95]. While many 
studies have used multiple step purifications using two chromatography techniques and 
series or combination of chromatography and ultrafiltration as we saw in Table 2-3 and 
Table 2-4. So comparing size of membranes used for retaining virus, we are able to retain 
small virus using micro-filters. This can reduce the cost related to ultrafiltration in terms 
of cost of membranes, pressure requirements for the system. Also using large pore size 
membranes can reduce pore plugging due to small debris, protein contaminants blocking 
the small pores of ultrafiltration membranes. In section 2.4, we have seen recovery and 
purification of viruses using multiple chromatography steps. Using set of 
chromatography was able to get high purity and product recovery was still moderate as 
40% to 70% [65, 75,78, 80]. With ultrafiltration using small pore sized membranes 
literature have shown moderate recoveries and used final polishing step such as 
chromatography to get high purity [90, 92, 96, 98]. With our approach, we were able to 
get moderate recovery using large pore size filters and high recovery with 300 kDa for 
PPV. For SINV moderate recovery is seen with 0.2 μm filter, which is usually used for 
larger particle filtration. In normal conditions, without virus flocculation 0.2 μm filters 
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will not be able to retain small viral particles of size 50nm. High recovery was obtained 
using 0.1 μm and 500 kDa filter. From our purification data, PPV purification was good 
and acceptable as per industrial requirements [101]. While in industry or in literature 
review we saw that high purification was achieved using multiple steps or combination of 
different steps. Using osmolyte flocculation can be developed and used as a platform 
approach. In terms of DNA removal, we can improve purity by using endonuclease 
treatment to remove more DNA content from the virus retentate product [86, 122]. 
As we study and compare the results for no flocculation time between fraction with 
increased flocculation time, we only observe an improvement in the recovery in the 2nd 
fraction for SINV, while with PPV recovery, we are not getting any improvement. 
Comparing the size of both viruses, PPV virus is a non-enveloped virus and has smaller 
capsid while SINV is an enveloped and contains outer lipid layer. SINV is bigger in size 
about 48-52 nm while PPV is the smallest parvovirus of size about 18-24 nm. The outer 
layer of viruses could be the decisive element in effective flocculation with osmolyte as 
the interactions for aggregations may change with the presence or absence of enveloped 
bilayer on virus particles. As we are performing recovery of virus particles using larger 
pore size filters the size of aggregated virus plays an important role. 
While we are able to show advantage of using flocculation and microfiltration, we 
anticipate some disadvantages to our process. We have seen that virus flocs are not 
permanent and can be broken with disturbances or agitation in the mixture. It is both 
good and bad for the system. It is good because after product recovery, we don’t have to 
worry about breaking flocs with other treatment. Flocculated particles can be easily 
dispersed in buffer such as PBS. It is not good for the recovery of viruses, as breaking of 
flocs allows particles to pass through the membrane and reduces overall yield. We have 
seen addition of mannitol for 2nd and 3rd fractions created disturbances in system and 
recovery was reduced. This is an important factor for consideration while designing large 
scale configuration for this approach it is important factor. Using large scale tank reactor 
similar to Amicon filtration cells we have used and allowing quiescent time after addition 
of virus and osmolyte for flocculation without disturbances in the system is 
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recommended. Allowing dormant time at ambient temperature for flocculation can be 
disadvantageous for some sensitive products which are susceptible to reduced activity at 
room temperature.  
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5. Conclusions and future work 
 
5.1.  Conclusion 
This work describes the purification of two viruses using a common, novel 
flocculant, mannitol. As mannitol is currently used as therapeutic substance for treatment 
in diuretic conditions, brain swelling conditions it is acceptable as biological drug and is 
FDA approved [8, 9]. PPV being smallest parvovirus of size about 20-24 nm [13, 14], is 
difficult to recover using filtration methods. However, with our novel approach of 
flocculation using 1M mannitol, we were able to form flocs that could be removed with 
larger pore size filters. Using a diafiltration method, we were able to recover infectious 
particles in the retentate. We explored the effect of different pore size filters, ranging 
from 0.2 µm to a 300 kDa MWCO filter. We have successfully shown that 58% of 
infectious PPV can be recovered with a 0.1 µm filter and 65% of infectious SINV. The 
PPV had an 85% reduction in contaminating proteins, while SINV had low protein 
removal of 37%. We were able to get no significant improvement for the non-enveloped 
PPV, and only a significant improvement can be seen in case of enveloped SINV for the 
2nd fraction. Time is still a variable that may need further study. The flocculation process 
was not able to get high removal of DNA content as it was also retained in the retentate 
with virus particles. Compared to control studies, we can see that mannitol was 
aggregating DNA content as well while in case of control study DNA content was 
removed. We therefore propose to use benzonase to reduce the size of the DNA prior to 
flocculation in order to inhibit DNA flocculation with mannitol. TEM images for PPV 
flocculation provide good support to our theory and all work shown in this research.  
Our recovery results show that mannitol flocculation followed by diafiltration is able 
to recover an enveloped and non-enveloped virus and purify a non-enveloped virus.  Our 
platform approach can be used as a potential method to replace chromatography and 
nanofiltration. This results can be used for future work and can be applied to large to 
medium scale to develop an industrial processing protocol. Adding advantages over 
replacing multiple traditional and expensive methods as chromatography or 
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ultrafiltration, new platform approach can be an effective new method in new vaccine 
production setups. 
   
  
 61 
5.2. Future Work:  
Currently, we have shown high recovery for an enveloped and non-enveloped virus 
and purification for a non-enveloped virus using batch diafiltration. The traditional batch 
diafiltration approach is applicable in lab scale models, but is not a good choice for 
industrial scale. We would like to develop this diafiltration method into a continuous 
process by incorporating continuous method with recycling of osmolyte solution. 
Currently our setup for diafiltration includes manual addition of mannitol solution into 
the filter unit. By using mannitol reservoir tank incorporated with pressure application, it 
can be used in a continuous diafiltration mode. For improved recovery of viruses, we 
would like to explore if we can change the hydrophobicity while performing the 
flocculation step. Increasing the hydrophobic interactions by addition of ethanol to the 
flocculation solution may affect the flocculation of viruses. Presence of polar group on 
ethanol enhances the hydrophobic nature of ethanol and when added to virus solution it 
should add effective hydrophobic forces on virus particles. Studies have shown increase 
in hydrophobicity with increasing concentration of ethanol on membranes [123, 124]. To 
overcome the current challenge for DNA removal, we can use benzonase treatment for 
efficiently remove DNA content while performing diafiltration method for higher 
purification. Benzonase nuclease is endonuclease enzyme which can degrade DNA and 
RNA which are considered as contaminant from host cells [86, 122]. Our preliminary 
data using benzonase nuclease treatment with PPV prior to flocculation and diafiltration 
decreased the initial DNA content and showed high DNA removal (data not shown) as 
compared to given results in section 4.1.5. 
We are interested in trying both enveloped and non-enveloped virus flocculation 
using another osmolyte, glycine, which has been demonstrated for virus removal in 
previous studies in our lab [6] and show promise as a flocculant for both viruses. In 
addition, we would like to perform flocculation experiments with different viruses such 
as minute virus of mice (MVM) and phage MS2. In the future, we will focus on improved 
purification and recovery of viruses by capture with charged anion membranes for 
vaccine manufacturing. Using charged anion membranes can help for recovery based on 
size of virus particles as well as surface charges of viruses. These membranes can be used 
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in bind and elute mode, similar to standard chromatography, and would allow for better 
clearance of impurities. 
To develop this method as an acceptable platform approach, I would like to work on 
creating large scale module for this method. Demonstrating that osmolyte flocculation is 
easily scalable, this experiments can be performed at large scale of 400 ml. Using 
continuous diafiltration method, removing the need to manual addition of osmolyte 
system can work in continuous manner and more likely decrease the disturbances in 
system which are responsible for breaking up the aggregates. More detailed results can be 
obtained regarding membrane permeability, reflux effect, flow rate by using pressure 
transducers, flow rate controllers for monitoring inlet to outlet pressure ratios, flow rate 
changes in the system. This setup would be similar to the current filtration systems as 
commercially available TFF or NFF systems with tank reactor operated in normal flow 
direction or dead end filtration. Tank reactor for holding flocculation mixture with 
replaceable filter membranes holder and standard tubing. The inlet and outlet will be 
connected with inline pressure sensors to determine the change in efficiency of flow 
across the membrane by monitoring pressure changes. Such systems are currently 
common in industry for virus purification with TFF which are scalable from pilot plant to 
large scale production. Instead of using multiple ultrafiltration filtration steps, we can 
introduce flocculation and microfiltration setup. 
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